ICAM ‐1 mediated inhibition of microglial inflammation through ERK / STAT3 signalling pathway improves cognitive functions in 5xFAD mouse model of Alzheimer's disease
The FEBS Journal · 2026
DOI: 10.1111/febs.70531 ↗At a glance
Journal article in The FEBS Journal, 2026. Written by Soumita Goswami and 2 co-authors. Institution: Cell Biology and Physiology Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India. Major MEDLINE topics: Alzheimer Disease, Microglia, Intercellular Adhesion Molecule-1, STAT3 Transcription Factor. 114 references. Funded by: CSIR - Indian Institute of Chemical Biology.
Topics: Demenz
Abstract (original language)
Microgliosis is one of the early hallmarks of Alzheimer's disease (AD) that plays a crucial role in disease pathogenesis. Microglia play a defensive role by phagocytosing and clearing amyloid‐β (Aβ) aggregates. However, excessive uptake of Aβ leads to impairment of its clearing ability, which results in neuroinflammation and eventually neurodegeneration. Thus, enhancing microglial phagocytosis and reducing its pro‐inflammatory functions are promising strategies for AD therapy. However, harnessing microglial activation for long‐term benefits in controlling disease pathogenesis in AD is currently lacking. Our recent findings revealed that the astrocyte secreted cytokine Intercellular adhesion molecule 1 (ICAM‐1) improves memory and cognitive impairments in a 5xFAD mouse model of AD. Here, we investigated the involvement of microglia in ICAM‐1 function since its receptor, LFA‐1, is expressed in microglia. We found that ICAM‐1 blocks Aβ‐mediated microglial inflammatory activation by inhibiting the ERK‐STAT3 pathway, which is indispensable for microglial inflammation. Further, we found that ICAM‐1 potentiates microglial phagocytic ability to eliminate Aβ in primary culture. Additionally, ICAM‐1 reduced Aβ plaque load and associated microglial reactivation in the 5xFAD mouse hippocampus. This reduction in plaque‐associated microgliosis led to improved synaptic protein expressions which was reflected in significant cognitive improvement. Moreover, blocking the binding between ICAM‐1 with its receptor LFA‐1 partially reduced ICAM‐1‐mediated microglial modification. Collectively, these findings suggest that ICAM‐1 plays a pivotal role in modifying microglial phagocytic and inflammatory functions via the ERK‐STAT3 signalling pathway, thereby contributing to Aβ clearance and cognitive improvements.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Cell Biology and Physiology Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India.
- Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.
ORCID profiles: Subhas Chandra Biswas
Funding
- CSIR - Indian Institute of Chemical Biology
Cite
APA
Goswami, S., Gorai, N., & Biswas, S. C. (2026). ICAM ‐1 mediated inhibition of microglial inflammation through ERK / STAT3 signalling pathway improves cognitive functions in 5xFAD mouse model of Alzheimer's disease. The FEBS Journal. https://doi.org/10.1111/febs.70531
Vancouver
Goswami S, Gorai N, Biswas SC. ICAM ‐1 mediated inhibition of microglial inflammation through ERK / STAT3 signalling pathway improves cognitive functions in 5xFAD mouse model of Alzheimer's disease. The FEBS Journal. 2026. doi:10.1111/febs.70531
BibTeX
@article{Goswami2026,
author = {Goswami, Soumita and Gorai, Nimai and Biswas, Subhas Chandra},
title = {ICAM ‐1 mediated inhibition of microglial inflammation through ERK / STAT3 signalling pathway improves cognitive functions in 5xFAD mouse model of Alzheimer's disease},
journal = {The FEBS Journal},
year = {2026},
doi = {10.1111/febs.70531}
}
EUVIMED